Knight Therapeutics Inc. (TSX:GUD)

Knight Therapeutics Cash Flow Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-5.37	4.33	-16.84	-29.89	15.68
Depreciation & Amortization	56.57	53.11	50.4	62.62	47.92
Stock-Based Compensation	8.11	1.86	2.33	1.89	3.05
Other Adjustments	7.75	-3.4	28.06	15.85	-22.64
Changes in Other Operating Activities	1.89	-19.62	-28.01	-5.47	0.63
Operating Cash Flow	68.96	36.28	35.94	45	44.62
Operating Cash Flow Growth	90.07%	0.95%	-20.14%	0.86%	-
Capital Expenditures	-1.91	-2.47	-0.95	-2.89	-3.83
Sale of Property, Plant & Equipment	0.03	0.1	1.92	-	-
Purchases of Intangible Assets	-31.79	-29	-9.01	-22.93	-220.35
Purchases of Investments	-70.39	-162.57	-334.16	-188.21	-64.32
Proceeds from Sale of Investments	138.98	210.91	371.54	150.95	183.23
Payments for Business Acquisitions	-110.08	-	-	-	-
Investing Cash Flow	-75.16	16.96	29.34	-63.08	-105.28
Long-Term Debt Issued	112.07	3.47	4.8	51.78	9.42
Long-Term Debt Repaid	-87.2	-17.61	-19.97	-17.54	-20.6
Net Long-Term Debt Issued (Repaid)	24.87	-14.14	-15.17	34.24	-11.18
Issuance of Common Stock	0.51	1	0.38	0.34	0.3
Repurchase of Common Stock	-6.35	-8.87	-53.48	-30.07	-64.42
Net Common Stock Issued (Repurchased)	-5.84	-7.86	-53.1	-29.73	-64.12
Other Financing Activities	-11.72	-11.54	-12.73	-7.27	-3.02
Financing Cash Flow	5.41	-33.54	-81	-2.76	-78.31
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-2.86	1.64	2.8	6.55	-4.66
Net Cash Flow	-0.8	19.7	-15.72	-20.84	-138.97
Free Cash Flow	67.05	33.81	34.99	42.12	40.79
Free Cash Flow Growth	98.30%	-3.37%	-16.92%	3.26%	-
FCF Margin	14.90%	9.11%	10.66%	14.35%	16.75%
Free Cash Flow Per Share	0.67	0.33	0.33	0.37	0.33
Levered Free Cash Flow	74.72	18.93	-15.73	44.55	40.22
Unlevered Free Cash Flow	54.21	38.41	18.54	13.22	31.88

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.